Plasma sphingolipids: Potential biomarkers for severe hepatic fibrosis in chronic hepatitis C
- Authors:
- Published online on: February 17, 2015 https://doi.org/10.3892/mmr.2015.3361
- Pages: 323-330
Abstract
Introduction
Hepatitis C is a disease of global epidemic status, the prevalence of which is >2%, with >120 million individuals infected with the hepatitis C virus (HCV) (1). Chronic HCV infection may eventually progress to severe fibrosis or cirrhosis, which necessitates surveillance for hepatocellular carcinoma and screening for varices (2). A natural history study revealed that a quarter of patients with chronic hepatitis C (CHC) with severe liver fibrosis succumbed after a median interval of 3.5 years, although this poor prognosis was improved following combination antiviral treatment (3). Therefore, the evaluation of severe hepatic fibrosis involves assessing the prognosis of, and developing a treatment strategy for, patients with CHC. Although a liver biopsy is the gold standard for assessing the stage of hepatic fibrosis, its clinical application is usually limited due to the invasiveness of this procedure. In addition, factors such as the sampling and observational methods also impact the veracity and the reliability of the results (4–5). Serological markers with easy accessibility, are the primary factor used to assist in evaluating liver fibrosis. However, the insufficient validation of their function means they are inadequate for accurately monitoring changes in the stages of fibrosis in CHC (4). Therefore, it is necessary to identify novel and effective noninvasive markers for the diagnosis and treatment of hepatic fibrosis, particularly for severe fibrosis in CHC.
Sphingolipids, consisting of a sphingosine backbone, are fundamental structural components of cell membranes and incorporate other constituents in order to form lipid rafts (6). Certain receptors or kinases are associated with lipid rafts, which form platforms that function in signaling and trafficking on the plasma membrane, and sphingolipids are involved in the regulation of signaling pathways in cell growth, differentiation and apoptosis (7,8). During HCV infection, the HCV RNA level may be significantly reduced if the gathering of non-structural proteins of HCV on lipid rafts is disrupted via the inhibition of serine-palmitoyltransferase, a key enzyme in the de novo synthesis of sphingolipids (9,10). Thus, host sphingolipids may impact upon the infection process of HCV and may reflect the disease status of the HCV infection. In addition, sphingolipids also have the potential to affect the pathogenesis of tissue fibrosis (11). Sphingosine 1-phosphate (S1P), as a bioactive lipid mediator, is involved in numerous signaling pathways and regulates a wide variety of cellular functions (12). It has been shown that the signaling axis with which S1P is involved, exerts a powerful migratory effect on hepatic myofibroblasts and is involved in the development of hepatic fibrosis (13). Therefore, it is hypothesized that sphingolipids may be associated with hepatic fibrogenesis. Although a clinical study looking at a single sphingolipid in CHC, in the case of S1P declining in CHC patients has been previously reported (14), the study of the full plasma sphingolipid profile in hepatic fibrosis induced by HCV has not been previously investigated, to the best of our knowledge, and little is currently known regarding the diagnostic value of plasma sphingolipids.
A mature high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method was previously established (15), and has been employed to identify an association between plasma sphingolipids and hepatic inflammation in CHC, using improved quantitative high-throughput lipidomic platform (16). The present study, based on liver biopsies, analyzed alterations in the plasma profile of sphingolipids of a cohort of untreated patients with CHC, with and without severe fibrosis, using HPLC-MS/MS. This approach was intended to identify the plasma sphingolipids that are associated with the development of severe fibrosis, in particular, severe fibrosis in patients with CHC who have developed significant fibrosis (Metavir F ≥2).
Patients and methods
Patients
A cohort of 122 patients from Dingxi (Gansu, China) were enrolled in the present study at Beijing YouAn Hospital, Capital Medical University (Beijing, China) between July 2010 and June 2011. All patients had a history of paid plasma donation between 1992 and 1995. The diagnosis of CHC was made in accordance with previously described criteria (2,17). Other viral co-infections, including the hepatitis B virus, or other liver diseases were excluded. No patients had received antiviral therapy prior to enrolment in the present study. Two patients were excluded from the study due to the collection of an invalid specimen from the liver biopsy or due to the presence of ascites unsuitable for puncture, as this increase the risk of intra-abdominal infection during biopsy. Thus, 120 patients were eligible for the study. Based on the liver biopsy, 64 patients with significant hepatic fibrosis (F ≥2) were eligible for subgroup analysis.
Blood from the cubital veins of fasting patients was collected on the day of the biopsy. Routine serological indicators, such as liver function, blood cell analysis and serum fibrosis marker assessment, were measured in all patients. Each patient provided written informed consent at the beginning of the study. The study protocol was conducted in accordance with the provisions of the Declaration of Helsinki and its revision, and was approved by the ethical committee of Beijing YouAn Hospital, Capital Medical University (Beijing, China).
Liver biopsy
Ultrasound-guided liver biopsy examination was employed in the present study. The specimens included at least six complete portal areas and the length was >1.5 cm. Liver biopsy specimens were fixed in formalin and embedded in paraffin. Biopsy specimens were independently evaluated for fibrosis status, using the Metavir scoring system, by two senior pathologists who were blinded to the clinical data (18,19). The fibrosis score was assessed on a five point scale (F0, no fibrosis; F1, portal fibrosis without septa; F2, few septa; F3, numerous septa without cirrhosis; and F4, cirrhosis; Fig. 1). Significant hepatic fibrosis was defined as F ≥2, while severe hepatic fibrosis was defined as F ≥3.
HPLC-MS/MS analysis
Blood samples from patients were collected into sterile tubes using cold lithium heparin as an anticoagulant and immediately centrifuged at 4°C at 8,000 × g for 10 min. The plasma samples were stored at −80°C. All lipid standards were purchased from Avanti Polar Lipids (Alabaster, AL, USA). Ultra Resi-analyzed grade methanol and HPLC grade methyl-tert-butyl ether were purchased from Mallinckrodt Baker Inc. (Phillipsburg, NJ, USA). Formic acid of analytical grade was obtained from Tedia Company (Fairfield, OH, USA). Ammonium formate (purity, >99.99%) was purchased from Sigma-Aldrich (St. Louis, MO, USA). Ultra-pure water was prepared using a Milli-Q purification system (Millipore, Bedford, MA, USA), HPLC-MS/MS was performed on an Agilent 6410B Triple Quad mass spectrometer (QQQ; Agilent Technologies Inc., Santa Clara, CA, USA) comprising a triple quadrupole MS analyzer with an electrospray ionization interface and an Agilent 1200 RRLC system. Sphingolipidomic assays were performed at the Institute of Materia Medica, Peking Union Medical College (Beijing, China) as previously described (15).
Statistical analysis
Results are expressed as the mean ± standard deviation unless otherwise stated. Depending on data distribution, the continuous variables that differed significantly between two groups were identified by an independent samples t-test or a Mann-Whitney test. Categorical variables were compared using Pearson’s χ2 test. The stepwise forward multivariate logistic regression analysis was performed and the P-values of entry and removal were respectively set to 0.05 and 0.1. The diagnostic value of plasma sphingolipids with significant differences and regression model in multivariate analysis were assessed using the area under the receiver operating characteristic (ROC) curve. The negative predictive value (NPV) and positive predictive value (PPV) were also generated. Statistical analysis was performed using SPSS version 19.0 (IBM, Armonk, NY, USA). P<0.05 was considered to indicate a statistically significant difference.
Results
Characteristics of the untreated CHC cohort
Characteristics of the patients with CHC who were included are summarized in Table I. A total of 120 CHC patients from the original cohort were eligible for the present study, with a mean age of 51.33 years. The average level of serum aminotransferase was mildly elevated compared with the normal range (<40 U/l). Based on liver fibrosis staging of the liver biopsy samples (Fig. 1), F1 was assigned to 55 patients, which accounted for the largest proportion (45.8%) of the cohort; F2 was assigned to 41.7% (50/120) of the patients; F3 was assigned to 10.0% (12/120) of the patients; while F0 and F4 were assigned to 1 (0.8%) and 2 (1.7%) patients, respectively.
Plasma sphingolipid profile in CHC between F ≤2 and F >2
Using the improved quantitative high-throughput lipidomic platform, a total of 44 plasma sphingolipids were detected in patients with CHC through HPLC-MS/MS. A statistically significant difference was observed between the F ≤2 and F >2 groups in plasma hexosylceramide (HexCer; d18:1/12:0), HexCer (d18:1/16:0) and HexCer (d18:1/22:0; P<0.05; Fig. 2). No statistical differences were identified in the remaining plasma sphingolipids (P>0.05).
Indicators associated with severe fibrosis (F ≥3) in CHC
Using univariate analysis, the routine serological indicators, alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin, prealbumin, γ-glutamyl transpeptidase (GGT), hyaluronic acid, hemoglobin, platelets, type III procollagen peptide, and type IV collagen were shown to be statistically different (P<0.05) between the F ≤2 and F ≥3 groups (Table II). For the multivariate analysis, HexCer (d18:1/12:0), HexCer (d18:1/16:0), HexCer (d18:1/22:0), ALT, AST, albumin, GGT, platelets, type III procollagen peptide, hyaluronic acid and type IV collagen were included in the forward stepwise logistical regression. The results demonstrated that HexCer (d18:1/12:0), ALT and AST were retained in the logistical regression equation. HexCer (d18:1/12:0), with an odds ratio (OR) value of 1.03, was associated with the presence of severe hepatic fibrosis (Table II). In addition, the area under the curve (AUC) of HexCer (d18:1/12:0), used to identify severe hepatic fibrosis, presented with 0.69 (P=0.024) via ROC analysis. Its NPV and PPV were 100% and 17.3%, respectively. Additionally, the distinguishing ability of the three indicators combined logistic regression equation was also evaluated using ROC analysis. The results revealed that the AUC of the three indicators in the combined model was 0.82 (P<0.001), and the sensitivity and specificity were 71.4% and 89.6%, respectively. The NPV and PPV were 95.9% and 47.6% respectively (Fig. 3A and B).
 | Table IIIndicators associated with severe fibrosis (F ≥3) in patients with CHC in univariate and multivariate analysis. |
Indicators associated with presence of severe fibrosis (F ≥3) in CHC with significant fibrosis (F ≥2)
In order to identify potential markers associated with the presence of severe hepatic fibrosis (F ≥3) in patients with CHC who had developed significant fibrosis (F ≥2), data were analyzed using univariate and multivariate analysis (Table III). A total of 64 patients with CHC who had significant fibrosis were eligible for analysis. According to the results of the univariate analysis, ALT, AST, prealbumin, GGT, platelets, hyaluronic acid, HexCer (d18:1/12:0), HexCer (d18:1/16:0) and HexCer (d18:1/24:0) exhibited a significant difference (P<0.05) between the F ≥2 and F ≥3 groups. When all the indicators that exhibited a significant difference were included in the forward stepwise logistic regression, only HexCer (d18:1/12:0) and AST were retained in the regression equation. These variables exhibited a close association with severe fibrosis, with ORs of 1.08 and 1.01 respectively. The ability to identify severe fibrosis in patients with CHC who had significant fibrosis (F ≥2) was also analyzed using the ROC curve. The results demonstrated that HexCer (d18:1/12:0) had an AUC value of 0.73 (P=0.009), with an NPV and PPV of 100 and 17.2%, respectively. Additionally, the AUC of this equation, including HexCer (d18:1/12:0) and AST, reached 0.79 (P=0.001), and the NPV and PPV reached 96.3% and 35.2%, respectively (Fig. 3C and D).
| Table IIIIndicators associated with severe fibrosis (F ≥3) in patients with CHC with significant fibrosis (F ≥2). |
Discussion
Although a clinical study looking at a single sphingolipid in CHC, in the case of S1P declining in CHC patients, has been previously reported, (14), to the best of our knowledge, there have been no studies that have investigated the full plasma sphingolipid profile, in order to identify biomarkers associated with the development of hepatic fibrosis induced by HCV. For the first time, to the best of our knowledge, the present study used liver biopsies and the HPLC-MS/MS method to provide a plasma sphingolipid profile of untreated patients with CHC, with and without severe hepatic fibrosis, and demonstrated that the plasma sphingolipid, HexCer (d18:1/12:0), may have a close association with the formation of severe hepatic fibrosis in CHC, in particular in patients with CHC who have developed significant fibrosis. Additionally, plasma HexCer (d18:1/12:0) may be used as a potential marker for patients with CHC with severe hepatic fibrosis.
In the present study, the plasma sphingolipid profile was analyzed in a cohort of 120 untreated patients with CHC, who had chronic HCV infection for ~20 years, which had been contracted from previous paid plasma donations. This cohort of patients with CHC were a suitable group to investigate as they lived in close proximity to each other and reported similar lifestyles in terms of diet and living environment. Although the incidence of severe fibrosis in this cohort was not high, it did reflect the alteration in plasma sphingolipids precisely, according to the different stages of fibrosis in the context of the treatment-naïve status. Using the improved quantitative high-throughput lipidomic methods (16), the results of the plasma sphingolipid profile showed different levels of plasma sphingolipids in patients with CHC, with and without severe hepatic fibrosis. The altered plasma levels of HexCer (d18:1/12:0), HexCer (d18:1/16:0) and HexCer (d18:1/22:0) were observed to be associated with the presence of severe fibrosis. Following adjustment for confounding indicators, HexCer (d18:1/12:0) remained closely associated with severe fibrosis. This indicated that elevated plasma HexCer (d18:1/12:0) may be implicated in the pathogenesis of severe fibrosis in CHC. At present, there is no direct evidence for the role of this specific glycosphingolipid in the pathogenesis of severe fibrosis due to CHC. A possible mechanism has been demonstrated in a previous study using an animal model, which reported that exogenous administration of α-galactosylceramide accelerated carbon tetrachloride-induced liver fibrosis in vivo through the activation of invariant natural killer T cells (20). This may suggest that glycosphingolipids contribute to the progression of liver fibrosis. However, further experimental studies are required to determine the underlying mechanisms responsible for the association of HexCer (d18:1/12:0) with severe hepatic fibrosis in CHC.
The primary concern in CHC is the occurrence and slow evolution of fibrosis over a number of years, culminating in cirrhosis. A large scale clinical study revealed that severe fibrosis may go undetected, with few or no clinical symptoms and signs (21). Additionally, a previous study confirmed that the rate of progression to cirrhosis is accelerated in patients whose initial biopsies exhibited septal fibrosis (F ≥2) and that these individuals are at an increased risk of developing advanced cirrhosis over the ensuing decade (22,23). Therefore, it is also important to examine the mechanisms underlying the evolution of fibrosis, as well as markers of severe fibrosis, which may provide insight into possible therapeutic targets to prevent the formation of severe fibrosis in patients with CHC who have developed septal fibrosis (F ≥2). In the present study, the plasma sphingolipids associated with severe fibrosis were evaluated in patients with CHC who had significant fibrosis (F ≥2). It is noteworthy that HexCer (d18:1/12:0), which was closely associated with severe fibrosis in all patients with CHC, following adjustment for confounding factors, also exhibited a correlation in a multivariate regression model, and demonstrated an association with the presence of severe fibrosis in the population of patients with CHC who had developed significant fibrosis. Therefore, it is hypothesized that HexCer (d18:1/12:0) may contribute to the development of advanced cirrhosis in patients with septal fibrosis (F ≥2).
ROC analysis was performed in the present study. It was shown that plasma HexCer (d18:1/12:0), with an AUC of 0.69, had the diagnostic ability to distinguish severe fibrosis in CHC. In addition, in multivariate analysis, the AUC of the indicators retained in the regression model was increased in the combined model, indicating severe fibrosis. This suggested that HexCer (d18:1/12:0) has potential as a noninvasive diagnostic indicator of severe hepatic fibrosis in CHC. This diagnostic ability may be strengthened when measurement of HexCer (d18:1/12:0) is combined with that of serum aminotransferase levels. Furthermore, the present study also identified that HexCer (d18:1/12:0) had acceptable diagnostic ability (AUC=0.73) with which to identify severe hepatic fibrosis in patients with CHC who had developed significant fibrosis. Similarly, the final regression model, including HexCer (d18:1/12:0), exhibited an improved diagnostic ability. Therefore, based on the results of the ROC analysis, HexCer (d18:1/12:0) may be utilized as a noninvasive marker to detect the presence of severe hepatic fibrosis in CHC, in particular in patients with CHC who have progressed to a significant stage of fibrosis.
Issues remain concerning the precise mechanisms underlying the pathogenesis of CHC, which were not included in the present study. In addition, CHC plasma donor with the same background were selected from a cohort that has had a long-term follow up. The relatively small sample size was a limitation of the present study. The diagnostic capacity of HexCer (d18:1/12:0) requires large scale clinical evaluation in the future.
In conclusion, for the first time, to the best of our knowledge, the present study analyzed the plasma sphingolipid profile in patients with CHC, with and without severe fibrosis. Plasma HexCer (d18:1/12:0) exhibited a close association with the formation of severe fibrosis in CHC, in particular in patients with CHC who had developed significant fibrosis. The present study also provided a novel insight into the molecular mechanisms underlying the development of severe fibrosis in CHC. However, further experimental studies are required to determine the precise mechanisms underlying these associations.
Acknowledgments
The present study was supported by the National Science and Technology Key Project on ‘Major Infectious Diseases such as HIV/AIDS, Viral Hepatitis Prevention and Treatment’ (grant nos. 2012ZX10002004-006, 2012ZX10004904-003-001 and 2013ZX10002002-006), the Ministry of Science and Technology of the People’s Republic of China (grant no. 2012ZX09301002-006), the High Technical Personnel Training Item in the Beijing Health System (grant no. 2011-3-083), the Special Scientific Research Fund for Beijing Health Development (grant no. 2011-2018-04) and YouAn Scientific Research Fund for Liver Disease and HIV/AIDS (grant no. BJYAH-2011-045). The authors would like to thank all participants involved in the present study.
References
|
Mohd Hanafiah K, Groeger J, Flaxman AD and Wiersma ST: Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 57:1333–1342. 2013. View Article : Google Scholar | |
|
Ghany MG, Strader DB, Thomas DL and Seeff LB: Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 49:1335–1374. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Lawson A, Hagan S, Rye K, et al: The natural history of hepatitis C with severe hepatic fibrosis. J Hepatol. 47:37–45. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Sebastiani G and Alberti A: How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C? J Viral Hepat. 19(Suppl 1): 18–32. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Regev A, Berho M, Jeffers LJ, et al: Sampling error and intrao-bserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 97:2614–2618. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Lingwood D and Simons K: Lipid rafts as a membrane-organizing principle. Science. 327:46–50. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Milhas D, Clarke CJ and Hannun YA: Sphingomyelin metabolism at the plasma membrane: implications for bioactive sphingolipids. FEBS Lett. 584:1887–1894. 2010. View Article : Google Scholar : | |
|
Bartke N and Hannun YA: Bioactive sphingolipids: metabolism and function. J Lipid Res. 50(Suppl): S91–S96. 2009. View Article : Google Scholar : | |
|
Sakamoto H, Okamoto K, Aoki M, et al: Host sphingolipid biosynthesis as a target for hepatitis C virus therapy. Nat Chem Biol. 1:333–337. 2005. View Article : Google Scholar | |
|
Umehara T, Sudoh M, Yasui F, et al: Serine palmitoyltransferase inhibitor suppresses HCV replication in a mouse model. Biochem Biophys Res Commun. 346:67–73. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Shea BS and Tager AM: Sphingolipid regulation of tissue fibrosis. Open Rheumatol J. 6:123–129. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Strub GM, Maceyka M, Hait NC, Milstien S and Spiegel S: Extracellular and intracellular actions of sphingosine-1-phosphate. Adv Exp Med Biol. 688:141–155. 2010.PubMed/NCBI | |
|
Li C, Zheng S, You H, et al: Sphingosine 1-phosphate (S1P)/S1P receptors are involved in human liver fibrosis by action on hepatic myofibroblasts motility. J Hepatol. 54:1205–1213. 2011. View Article : Google Scholar | |
|
Ikeda H, Ohkawa R, Watanabe N, et al: Plasma concentration of bioactive lipid mediator sphingosine 1-phosphate is reduced in patients with chronic hepatitis C. Clin Chim Acta. 411:765–770. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Qu F, Wu CS, Hou JF, Jin Y and Zhang JL: Sphingolipids as new biomarkers for assessment of delayed-type hypersensitivity and response to triptolide. PLoS One. 7:e524542012. View Article : Google Scholar | |
|
Qu F, Zheng SJ, Wu CS, Jia ZX, Zhang JL and Duan ZP: Lipidomic profiling of plasma in patients with chronic hepatitis C infection. Anal Bioanal Chem. 406:555–564. 2014. View Article : Google Scholar | |
|
Hepatotogy Branch, Infectious and Parasitology branch, Chinese Medical Association: Guideline of prevention and treatment of hepatitis C. Zhonghua Yu Fang Yi Xue Za Zhi. 38:210–215. 2004. | |
|
Group TFMCS Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 20:15–20. 1994. View Article : Google Scholar | |
|
Bedossa P and Poynard T: An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 24:289–293. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Park O, Jeong WI, Wang L, et al: Diverse roles of invariant natural killer T cells in liver injury and fibrosis induced by carbon tetrachloride. Hepatology. 49:1683–1694. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Di Bisceglie AM: Natural history of hepatitis C: its impact on clinical management. Hepatology. 31:1014–1018. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Yano M, Kumada H, Kage M, et al: The long-term pathological evolution of chronic hepatitis C. Hepatology. 23:1334–1340. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Marcellin P, Asselah T and Boyer N: Fibrosis and disease progression in hepatitis C. Hepatology. 36:S47–S56. 2002. View Article : Google Scholar : PubMed/NCBI |
